Jon Matsumura
Concepts (463)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Vessel Prosthesis Implantation | 88 | 2026 | 219 | 14.990 |
Why?
| | Aortic Aneurysm, Abdominal | 73 | 2026 | 164 | 11.780 |
Why?
| | Blood Vessel Prosthesis | 60 | 2026 | 133 | 10.410 |
Why?
| | Endovascular Procedures | 53 | 2026 | 390 | 9.970 |
Why?
| | Aortic Aneurysm, Thoracic | 35 | 2026 | 135 | 7.750 |
Why?
| | Stents | 68 | 2025 | 554 | 7.560 |
Why?
| | Aorta, Thoracic | 27 | 2026 | 284 | 4.500 |
Why?
| | Carotid Stenosis | 23 | 2024 | 103 | 3.530 |
Why?
| | Prosthesis Design | 41 | 2026 | 358 | 3.380 |
Why?
| | Iliac Aneurysm | 9 | 2024 | 17 | 3.280 |
Why?
| | Vascular Surgical Procedures | 19 | 2018 | 352 | 2.370 |
Why?
| | Endarterectomy, Carotid | 14 | 2024 | 63 | 2.180 |
Why?
| | Aortography | 18 | 2025 | 54 | 2.120 |
Why?
| | Vascular System Injuries | 6 | 2024 | 79 | 2.100 |
Why?
| | Tomography, X-Ray Computed | 37 | 2025 | 2786 | 1.980 |
Why?
| | Treatment Outcome | 97 | 2026 | 11821 | 1.910 |
Why?
| | Aortic Diseases | 9 | 2025 | 125 | 1.900 |
Why?
| | Iliac Artery | 11 | 2024 | 53 | 1.800 |
Why?
| | Angioplasty | 12 | 2017 | 49 | 1.780 |
Why?
| | Computed Tomography Angiography | 8 | 2024 | 151 | 1.760 |
Why?
| | Aortic Rupture | 13 | 2026 | 28 | 1.720 |
Why?
| | Time Factors | 57 | 2026 | 7109 | 1.620 |
Why?
| | Aortic Aneurysm | 9 | 2024 | 69 | 1.530 |
Why?
| | Stroke | 18 | 2024 | 1287 | 1.450 |
Why?
| | Aged, 80 and over | 58 | 2026 | 8391 | 1.390 |
Why?
| | Angioplasty, Balloon | 9 | 2013 | 92 | 1.360 |
Why?
| | Aged | 108 | 2026 | 26432 | 1.290 |
Why?
| | Aorta, Abdominal | 9 | 2025 | 51 | 1.130 |
Why?
| | Postoperative Complications | 35 | 2025 | 3034 | 1.080 |
Why?
| | Risk Factors | 45 | 2026 | 10921 | 1.080 |
Why?
| | Endoleak | 11 | 2025 | 16 | 1.040 |
Why?
| | Sarcopenia | 2 | 2019 | 100 | 1.040 |
Why?
| | Prosthesis Failure | 11 | 2017 | 126 | 0.950 |
Why?
| | Prospective Studies | 39 | 2026 | 8123 | 0.940 |
Why?
| | Middle Aged | 82 | 2026 | 36619 | 0.920 |
Why?
| | Vascular Patency | 13 | 2025 | 115 | 0.900 |
Why?
| | Humans | 184 | 2026 | 146342 | 0.890 |
Why?
| | Subclavian Artery | 6 | 2022 | 28 | 0.890 |
Why?
| | Male | 123 | 2026 | 73396 | 0.860 |
Why?
| | Myocardial Infarction | 5 | 2024 | 1215 | 0.780 |
Why?
| | United States | 41 | 2025 | 16136 | 0.780 |
Why?
| | Female | 116 | 2026 | 79499 | 0.770 |
Why?
| | Femoral Artery | 4 | 2013 | 183 | 0.740 |
Why?
| | Predictive Value of Tests | 11 | 2025 | 2113 | 0.740 |
Why?
| | Vena Cava Filters | 5 | 2023 | 68 | 0.720 |
Why?
| | Ulcer | 3 | 2014 | 37 | 0.680 |
Why?
| | Risk Assessment | 21 | 2024 | 3712 | 0.660 |
Why?
| | Population Surveillance | 2 | 2021 | 481 | 0.650 |
Why?
| | Foreign-Body Migration | 3 | 2017 | 32 | 0.620 |
Why?
| | Alloys | 3 | 2024 | 36 | 0.600 |
Why?
| | Ischemia | 5 | 2018 | 421 | 0.600 |
Why?
| | Retrospective Studies | 44 | 2025 | 17438 | 0.590 |
Why?
| | Popliteal Artery | 4 | 2015 | 60 | 0.570 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 507 | 0.570 |
Why?
| | Marfan Syndrome | 1 | 2019 | 44 | 0.570 |
Why?
| | Psoas Muscles | 1 | 2018 | 24 | 0.560 |
Why?
| | Frailty | 2 | 2019 | 208 | 0.560 |
Why?
| | Reoperation | 13 | 2020 | 645 | 0.550 |
Why?
| | Body Composition | 2 | 2019 | 689 | 0.540 |
Why?
| | Doxycycline | 4 | 2025 | 61 | 0.510 |
Why?
| | Societies, Medical | 5 | 2020 | 907 | 0.510 |
Why?
| | Chlorhexidine | 1 | 2017 | 24 | 0.500 |
Why?
| | Decontamination | 1 | 2017 | 28 | 0.500 |
Why?
| | Anti-Infective Agents, Local | 1 | 2017 | 40 | 0.490 |
Why?
| | Health Care Costs | 3 | 2014 | 423 | 0.480 |
Why?
| | Elective Surgical Procedures | 8 | 2020 | 216 | 0.470 |
Why?
| | Wounds, Nonpenetrating | 6 | 2024 | 305 | 0.460 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 246 | 0.440 |
Why?
| | Infection Control | 1 | 2017 | 174 | 0.440 |
Why?
| | Radiography, Interventional | 5 | 2019 | 128 | 0.430 |
Why?
| | Education, Medical, Continuing | 2 | 2014 | 130 | 0.430 |
Why?
| | Thoracic Injuries | 3 | 2024 | 69 | 0.430 |
Why?
| | Follow-Up Studies | 26 | 2024 | 5439 | 0.420 |
Why?
| | Program Development | 2 | 2014 | 371 | 0.400 |
Why?
| | Patient Readmission | 3 | 2014 | 778 | 0.400 |
Why?
| | Lower Extremity | 1 | 2018 | 453 | 0.390 |
Why?
| | Vascular Diseases | 2 | 2014 | 252 | 0.390 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 349 | 0.390 |
Why?
| | Vascular Calcification | 2 | 2025 | 109 | 0.380 |
Why?
| | Kaplan-Meier Estimate | 10 | 2019 | 970 | 0.370 |
Why?
| | Health Expenditures | 1 | 2014 | 198 | 0.370 |
Why?
| | Carotid Artery Diseases | 3 | 2005 | 70 | 0.370 |
Why?
| | Congresses as Topic | 1 | 2014 | 226 | 0.370 |
Why?
| | Clinical Trials as Topic | 5 | 2026 | 1064 | 0.360 |
Why?
| | Skin | 1 | 2017 | 701 | 0.360 |
Why?
| | Asymptomatic Diseases | 5 | 2024 | 102 | 0.350 |
Why?
| | Patient Selection | 7 | 2021 | 728 | 0.350 |
Why?
| | Embolic Protection Devices | 1 | 2012 | 12 | 0.350 |
Why?
| | Constriction, Pathologic | 7 | 2023 | 240 | 0.330 |
Why?
| | Minimally Invasive Surgical Procedures | 7 | 2009 | 196 | 0.330 |
Why?
| | Thoracic Outlet Syndrome | 3 | 2001 | 14 | 0.330 |
Why?
| | Arterial Occlusive Diseases | 3 | 2008 | 88 | 0.330 |
Why?
| | Pulmonary Embolism | 2 | 2005 | 246 | 0.320 |
Why?
| | Thromboembolism | 1 | 2012 | 129 | 0.320 |
Why?
| | Severity of Illness Index | 9 | 2024 | 2921 | 0.310 |
Why?
| | Intracranial Embolism | 1 | 2010 | 34 | 0.310 |
Why?
| | Ultrasonography, Doppler, Duplex | 10 | 2017 | 39 | 0.310 |
Why?
| | Ultrasonography, Interventional | 3 | 2001 | 163 | 0.310 |
Why?
| | Filtration | 1 | 2010 | 68 | 0.310 |
Why?
| | Peripheral Vascular Diseases | 2 | 2004 | 102 | 0.310 |
Why?
| | Survival Rate | 11 | 2026 | 2092 | 0.310 |
Why?
| | Disease Progression | 6 | 2023 | 2867 | 0.300 |
Why?
| | Venous Thrombosis | 5 | 2005 | 199 | 0.290 |
Why?
| | Muscle, Skeletal | 1 | 2019 | 1818 | 0.290 |
Why?
| | Adult | 37 | 2024 | 41087 | 0.280 |
Why?
| | Chi-Square Distribution | 5 | 2014 | 517 | 0.280 |
Why?
| | Radiography | 7 | 2012 | 861 | 0.280 |
Why?
| | Stainless Steel | 2 | 2024 | 19 | 0.270 |
Why?
| | Iliac Vein | 2 | 2006 | 13 | 0.270 |
Why?
| | Thrombosis | 4 | 2018 | 398 | 0.260 |
Why?
| | Health Status | 4 | 2026 | 827 | 0.260 |
Why?
| | Regional Blood Flow | 4 | 2018 | 507 | 0.260 |
Why?
| | Paraparesis | 2 | 2008 | 7 | 0.250 |
Why?
| | Spinal Cord Ischemia | 2 | 2010 | 60 | 0.250 |
Why?
| | Hospitals, University | 1 | 2007 | 178 | 0.240 |
Why?
| | Graft Occlusion, Vascular | 4 | 2018 | 39 | 0.240 |
Why?
| | Blood Proteins | 2 | 2025 | 239 | 0.230 |
Why?
| | Endpoint Determination | 1 | 2026 | 84 | 0.230 |
Why?
| | Angiography | 5 | 2017 | 206 | 0.230 |
Why?
| | Hospital Mortality | 4 | 2020 | 1051 | 0.230 |
Why?
| | Ankle Brachial Index | 2 | 2018 | 41 | 0.230 |
Why?
| | Epidemiologic Research Design | 1 | 2005 | 27 | 0.230 |
Why?
| | Length of Stay | 6 | 2024 | 1358 | 0.220 |
Why?
| | Amino Acid Oxidoreductases | 1 | 2024 | 19 | 0.220 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2024 | 14 | 0.220 |
Why?
| | Retreatment | 2 | 2021 | 79 | 0.210 |
Why?
| | Erectile Dysfunction | 2 | 2023 | 35 | 0.210 |
Why?
| | Incisional Hernia | 1 | 2024 | 8 | 0.210 |
Why?
| | Femoral Vein | 3 | 2001 | 36 | 0.200 |
Why?
| | Matrix Metalloproteinase 3 | 1 | 2023 | 27 | 0.190 |
Why?
| | Reproducibility of Results | 4 | 2025 | 3416 | 0.190 |
Why?
| | Preoperative Care | 3 | 2017 | 396 | 0.190 |
Why?
| | Multicenter Studies as Topic | 3 | 2014 | 417 | 0.190 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 128 | 0.190 |
Why?
| | Registries | 3 | 2026 | 2400 | 0.180 |
Why?
| | Paraplegia | 4 | 2011 | 60 | 0.180 |
Why?
| | Catheterization, Peripheral | 3 | 2009 | 116 | 0.180 |
Why?
| | Comorbidity | 7 | 2019 | 1665 | 0.180 |
Why?
| | Carotid Artery, Internal | 5 | 2008 | 45 | 0.180 |
Why?
| | Equipment Design | 6 | 2011 | 520 | 0.180 |
Why?
| | Prosthesis Implantation | 2 | 2002 | 156 | 0.170 |
Why?
| | Aftercare | 2 | 2020 | 225 | 0.170 |
Why?
| | Double-Blind Method | 3 | 2023 | 2070 | 0.170 |
Why?
| | Odds Ratio | 3 | 2014 | 1077 | 0.170 |
Why?
| | Feasibility Studies | 7 | 2022 | 1135 | 0.160 |
Why?
| | Patients' Rooms | 1 | 2000 | 13 | 0.160 |
Why?
| | Hyperglycemia | 1 | 2024 | 384 | 0.160 |
Why?
| | Eligibility Determination | 1 | 2021 | 73 | 0.160 |
Why?
| | Logistic Models | 4 | 2015 | 2126 | 0.160 |
Why?
| | Collateral Circulation | 2 | 2010 | 20 | 0.160 |
Why?
| | Abdominal Oblique Muscles | 1 | 2019 | 1 | 0.150 |
Why?
| | Intercostal Muscles | 1 | 2019 | 4 | 0.150 |
Why?
| | Clinical Competence | 6 | 2019 | 1272 | 0.150 |
Why?
| | Cause of Death | 4 | 2019 | 456 | 0.150 |
Why?
| | Rectus Abdominis | 1 | 2019 | 16 | 0.150 |
Why?
| | United States Food and Drug Administration | 3 | 2009 | 208 | 0.150 |
Why?
| | Superficial Back Muscles | 1 | 2019 | 16 | 0.150 |
Why?
| | Oleic Acids | 1 | 1999 | 12 | 0.150 |
Why?
| | Spinal Fusion | 1 | 2022 | 265 | 0.150 |
Why?
| | Credentialing | 1 | 2019 | 21 | 0.150 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 640 | 0.150 |
Why?
| | Specialties, Surgical | 1 | 2020 | 88 | 0.140 |
Why?
| | Aneurysm, Ruptured | 2 | 2013 | 38 | 0.140 |
Why?
| | Netherlands | 3 | 2026 | 85 | 0.140 |
Why?
| | Observer Variation | 2 | 2018 | 356 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1203 | 0.140 |
Why?
| | Frail Elderly | 1 | 2019 | 141 | 0.140 |
Why?
| | Phosphatidylcholines | 1 | 1999 | 131 | 0.140 |
Why?
| | Liposomes | 1 | 2000 | 269 | 0.140 |
Why?
| | Genetic Therapy | 1 | 2000 | 303 | 0.140 |
Why?
| | Protease Inhibitors | 1 | 2019 | 103 | 0.140 |
Why?
| | Disease-Free Survival | 3 | 2017 | 778 | 0.140 |
Why?
| | Age Factors | 4 | 2026 | 3347 | 0.130 |
Why?
| | Electronic Mail | 1 | 2018 | 63 | 0.130 |
Why?
| | Surgeons | 1 | 2022 | 351 | 0.130 |
Why?
| | Curriculum | 1 | 2005 | 1079 | 0.130 |
Why?
| | Gene Transfer Techniques | 1 | 1999 | 185 | 0.130 |
Why?
| | Quality of Life | 5 | 2026 | 3200 | 0.130 |
Why?
| | Neck Muscles | 1 | 1997 | 21 | 0.130 |
Why?
| | Ribs | 1 | 1997 | 35 | 0.130 |
Why?
| | Limb Salvage | 1 | 2018 | 74 | 0.130 |
Why?
| | Anatomic Landmarks | 1 | 2017 | 31 | 0.130 |
Why?
| | Blood Vessels | 1 | 1999 | 164 | 0.130 |
Why?
| | Clavicle | 1 | 1997 | 38 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1942 | 0.130 |
Why?
| | Administration, Cutaneous | 1 | 2017 | 128 | 0.120 |
Why?
| | Critical Illness | 3 | 2018 | 908 | 0.120 |
Why?
| | Axillary Artery | 1 | 1996 | 14 | 0.120 |
Why?
| | Bile Pigments | 1 | 1996 | 2 | 0.120 |
Why?
| | Quality Assurance, Health Care | 2 | 2019 | 349 | 0.120 |
Why?
| | Endothelium, Vascular | 2 | 2000 | 952 | 0.120 |
Why?
| | Cholagogues and Choleretics | 1 | 1996 | 5 | 0.120 |
Why?
| | Bile | 1 | 1996 | 26 | 0.120 |
Why?
| | Cholelithiasis | 1 | 1996 | 37 | 0.120 |
Why?
| | Analysis of Variance | 2 | 2016 | 1298 | 0.120 |
Why?
| | Incidence | 7 | 2016 | 2936 | 0.110 |
Why?
| | Biomarkers | 2 | 2025 | 4340 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1763 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 474 | 0.110 |
Why?
| | Antioxidants | 1 | 2019 | 544 | 0.110 |
Why?
| | Sex Factors | 3 | 2026 | 2107 | 0.110 |
Why?
| | Survival Analysis | 6 | 2016 | 1378 | 0.110 |
Why?
| | Spinal Injuries | 1 | 1995 | 62 | 0.110 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 519 | 0.110 |
Why?
| | Evidence-Based Medicine | 4 | 2017 | 731 | 0.100 |
Why?
| | Chicago | 3 | 2011 | 62 | 0.100 |
Why?
| | Blood Glucose | 1 | 2024 | 2360 | 0.100 |
Why?
| | Prosthesis-Related Infections | 2 | 2008 | 100 | 0.100 |
Why?
| | Intermittent Claudication | 1 | 2015 | 121 | 0.100 |
Why?
| | Wisconsin | 1 | 2013 | 102 | 0.100 |
Why?
| | Hospital Costs | 1 | 2014 | 131 | 0.100 |
Why?
| | Hypertension | 2 | 2021 | 1272 | 0.100 |
Why?
| | Taurocholic Acid | 1 | 1993 | 8 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 597 | 0.100 |
Why?
| | Parenteral Nutrition, Total | 1 | 1993 | 27 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 582 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 1995 | 220 | 0.090 |
Why?
| | Aneurysm | 2 | 2003 | 37 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1101 | 0.090 |
Why?
| | Intestinal Absorption | 1 | 1993 | 103 | 0.090 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 365 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 196 | 0.090 |
Why?
| | Leg | 3 | 1999 | 246 | 0.090 |
Why?
| | Intraoperative Complications | 3 | 2019 | 157 | 0.090 |
Why?
| | Ileum | 1 | 1993 | 112 | 0.090 |
Why?
| | Postoperative Care | 1 | 2014 | 301 | 0.090 |
Why?
| | Europe | 1 | 2013 | 421 | 0.090 |
Why?
| | Device Approval | 2 | 2009 | 19 | 0.090 |
Why?
| | Communication | 1 | 2018 | 980 | 0.090 |
Why?
| | Permeability | 2 | 2009 | 166 | 0.090 |
Why?
| | Catheters | 1 | 2011 | 73 | 0.090 |
Why?
| | Viscera | 1 | 2011 | 17 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2009 | 1331 | 0.080 |
Why?
| | Acute Disease | 4 | 2024 | 1038 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2023 | 426 | 0.080 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 2010 | 9 | 0.080 |
Why?
| | Exercise Tolerance | 1 | 2013 | 289 | 0.080 |
Why?
| | Aneurysm, False | 1 | 2011 | 46 | 0.080 |
Why?
| | Residence Characteristics | 1 | 2013 | 385 | 0.080 |
Why?
| | Databases as Topic | 1 | 2010 | 70 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2219 | 0.080 |
Why?
| | Research Design | 3 | 2009 | 1143 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1543 | 0.080 |
Why?
| | Exercise Test | 1 | 2013 | 637 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2018 | 1210 | 0.080 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2009 | 26 | 0.080 |
Why?
| | Young Adult | 5 | 2024 | 14330 | 0.080 |
Why?
| | United States Department of Veterans Affairs | 1 | 2014 | 777 | 0.080 |
Why?
| | Radiography, Abdominal | 2 | 2001 | 44 | 0.080 |
Why?
| | Hospitals, Urban | 1 | 2010 | 140 | 0.080 |
Why?
| | Ischemic Attack, Transient | 2 | 2009 | 71 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2017 | 3017 | 0.070 |
Why?
| | Ambulatory Care | 1 | 2014 | 628 | 0.070 |
Why?
| | Genes, Reporter | 2 | 2000 | 275 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1327 | 0.070 |
Why?
| | Dilatation, Pathologic | 2 | 1999 | 60 | 0.070 |
Why?
| | Porosity | 1 | 2009 | 95 | 0.070 |
Why?
| | Plasmids | 2 | 2000 | 373 | 0.070 |
Why?
| | Telemedicine | 1 | 2018 | 966 | 0.070 |
Why?
| | Benchmarking | 1 | 2010 | 193 | 0.070 |
Why?
| | Extremities | 1 | 2009 | 142 | 0.070 |
Why?
| | Rupture | 1 | 2009 | 91 | 0.070 |
Why?
| | Carotid Arteries | 1 | 2010 | 206 | 0.070 |
Why?
| | Ultrasonography | 4 | 2014 | 788 | 0.070 |
Why?
| | General Surgery | 2 | 2014 | 217 | 0.070 |
Why?
| | Aorta | 2 | 2022 | 440 | 0.070 |
Why?
| | Anesthesiology | 1 | 1990 | 178 | 0.070 |
Why?
| | Treatment Failure | 2 | 2020 | 361 | 0.070 |
Why?
| | Coronary Artery Bypass | 2 | 2000 | 269 | 0.070 |
Why?
| | Carotid Artery Thrombosis | 1 | 2007 | 6 | 0.060 |
Why?
| | Organ Size | 2 | 2020 | 465 | 0.060 |
Why?
| | Equipment Safety | 2 | 2009 | 38 | 0.060 |
Why?
| | Calcinosis | 1 | 2009 | 231 | 0.060 |
Why?
| | Animals | 6 | 2024 | 38107 | 0.060 |
Why?
| | Patient Discharge | 1 | 2013 | 997 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2014 | 947 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2004 | 778 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2240 | 0.060 |
Why?
| | Arm | 2 | 1997 | 111 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2010 | 362 | 0.060 |
Why?
| | Prostheses and Implants | 1 | 2007 | 137 | 0.060 |
Why?
| | Polyesters | 1 | 2006 | 76 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2005 | 74 | 0.060 |
Why?
| | Hematoma | 1 | 2005 | 62 | 0.060 |
Why?
| | Vena Cava, Inferior | 2 | 2023 | 80 | 0.050 |
Why?
| | Recurrence | 3 | 2017 | 1133 | 0.050 |
Why?
| | Practice Guidelines as Topic | 4 | 2010 | 1591 | 0.050 |
Why?
| | Health Status Indicators | 1 | 2005 | 167 | 0.050 |
Why?
| | Renal Veins | 1 | 2004 | 16 | 0.050 |
Why?
| | Mesenteric Artery, Superior | 1 | 2004 | 28 | 0.050 |
Why?
| | Cohort Studies | 4 | 2026 | 6077 | 0.050 |
Why?
| | Hernia, Ventral | 1 | 2004 | 33 | 0.050 |
Why?
| | United Kingdom | 2 | 2003 | 377 | 0.050 |
Why?
| | High-Throughput Screening Assays | 1 | 2025 | 179 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2024 | 156 | 0.050 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2023 | 16 | 0.050 |
Why?
| | Fluoroscopy | 2 | 2001 | 179 | 0.050 |
Why?
| | Nephrectomy | 1 | 2004 | 172 | 0.050 |
Why?
| | Data Collection | 1 | 2006 | 650 | 0.050 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2024 | 271 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2024 | 208 | 0.050 |
Why?
| | Cerebrovascular Disorders | 2 | 2000 | 103 | 0.050 |
Why?
| | Leadership | 1 | 2007 | 414 | 0.050 |
Why?
| | Lumbosacral Region | 1 | 2022 | 58 | 0.050 |
Why?
| | Mass Spectrometry | 1 | 2025 | 729 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2000 | 4118 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 563 | 0.050 |
Why?
| | Illinois | 3 | 2008 | 47 | 0.040 |
Why?
| | Learning Curve | 1 | 2022 | 71 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2024 | 449 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2007 | 702 | 0.040 |
Why?
| | Arteries | 1 | 2023 | 261 | 0.040 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 2001 | 5 | 0.040 |
Why?
| | Time | 1 | 2002 | 85 | 0.040 |
Why?
| | Delphi Technique | 1 | 2023 | 350 | 0.040 |
Why?
| | Device Removal | 1 | 2023 | 149 | 0.040 |
Why?
| | Perfusion | 1 | 2023 | 255 | 0.040 |
Why?
| | England | 1 | 2001 | 106 | 0.040 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2001 | 6 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 449 | 0.040 |
Why?
| | Mesenteric Veins | 1 | 2001 | 28 | 0.040 |
Why?
| | Substance-Related Disorders | 1 | 1990 | 1100 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2024 | 322 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 115 | 0.040 |
Why?
| | Gene Targeting | 1 | 2000 | 76 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2005 | 1998 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2001 | 217 | 0.040 |
Why?
| | Peritoneum | 1 | 2000 | 44 | 0.040 |
Why?
| | Cerebral Angiography | 1 | 2000 | 121 | 0.040 |
Why?
| | Biomedical Research | 1 | 2007 | 729 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 228 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4580 | 0.040 |
Why?
| | Radiotherapy | 1 | 2001 | 209 | 0.040 |
Why?
| | Troponin T | 1 | 2000 | 63 | 0.040 |
Why?
| | Internship and Residency | 1 | 1990 | 1281 | 0.040 |
Why?
| | Cation Exchange Resins | 1 | 1999 | 7 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2000 | 105 | 0.040 |
Why?
| | Injury Severity Score | 2 | 2013 | 572 | 0.040 |
Why?
| | Spermine | 1 | 1999 | 29 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2001 | 1503 | 0.040 |
Why?
| | Rabbits | 1 | 2000 | 651 | 0.040 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 1999 | 21 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2020 | 122 | 0.040 |
Why?
| | Luciferases | 1 | 1999 | 153 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2001 | 185 | 0.040 |
Why?
| | Monitoring, Intraoperative | 1 | 1999 | 66 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 2000 | 132 | 0.040 |
Why?
| | Veins | 1 | 1999 | 68 | 0.040 |
Why?
| | Endoscopy | 1 | 2001 | 316 | 0.030 |
Why?
| | Prognosis | 3 | 2015 | 4351 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1408 | 0.030 |
Why?
| | Postoperative Period | 1 | 1999 | 355 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2000 | 292 | 0.030 |
Why?
| | Drug Carriers | 1 | 1999 | 138 | 0.030 |
Why?
| | Glycine | 1 | 1999 | 184 | 0.030 |
Why?
| | Arteriosclerosis | 1 | 1998 | 82 | 0.030 |
Why?
| | Subclavian Vein | 1 | 1997 | 15 | 0.030 |
Why?
| | Surgical Flaps | 1 | 1999 | 140 | 0.030 |
Why?
| | Administration, Oral | 1 | 2020 | 872 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 1998 | 164 | 0.030 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 1997 | 37 | 0.030 |
Why?
| | Transfection | 1 | 1999 | 916 | 0.030 |
Why?
| | Retroperitoneal Neoplasms | 1 | 1997 | 28 | 0.030 |
Why?
| | Multiple Trauma | 2 | 2010 | 118 | 0.030 |
Why?
| | Intraoperative Care | 1 | 1997 | 68 | 0.030 |
Why?
| | Hemodynamics | 2 | 2000 | 1114 | 0.030 |
Why?
| | Cholic Acids | 1 | 1996 | 13 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1361 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 6034 | 0.030 |
Why?
| | Veterans | 1 | 2008 | 1650 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 628 | 0.030 |
Why?
| | Atherosclerosis | 1 | 2019 | 410 | 0.030 |
Why?
| | Taurine | 1 | 1996 | 41 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 1999 | 533 | 0.030 |
Why?
| | Movement | 1 | 1997 | 290 | 0.030 |
Why?
| | Wound Healing | 1 | 1998 | 354 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1999 | 2022 | 0.030 |
Why?
| | Anticoagulants | 2 | 2016 | 746 | 0.030 |
Why?
| | Contrast Media | 1 | 1998 | 493 | 0.030 |
Why?
| | Bile Acids and Salts | 1 | 1996 | 163 | 0.030 |
Why?
| | Myocardium | 1 | 2000 | 948 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1999 | 1224 | 0.030 |
Why?
| | Gene Expression | 1 | 1999 | 1463 | 0.030 |
Why?
| | Sarcoma | 1 | 1997 | 209 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 330 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 517 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2861 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2001 | 1160 | 0.030 |
Why?
| | Lipids | 1 | 1999 | 714 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1493 | 0.020 |
Why?
| | Accidents, Traffic | 2 | 2005 | 193 | 0.020 |
Why?
| | Swine, Miniature | 1 | 1993 | 88 | 0.020 |
Why?
| | Mass Screening | 1 | 2001 | 1307 | 0.020 |
Why?
| | Least-Squares Analysis | 1 | 2012 | 73 | 0.020 |
Why?
| | Blood Flow Velocity | 2 | 2005 | 419 | 0.020 |
Why?
| | DNA | 1 | 1999 | 1421 | 0.020 |
Why?
| | Random Allocation | 1 | 1993 | 366 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 1993 | 432 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2012 | 122 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 3 | 2003 | 3926 | 0.020 |
Why?
| | Case-Control Studies | 2 | 2014 | 3647 | 0.020 |
Why?
| | Physician Impairment | 1 | 1990 | 15 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5899 | 0.020 |
Why?
| | Polytetrafluoroethylene | 2 | 2003 | 24 | 0.020 |
Why?
| | Swine | 1 | 1993 | 821 | 0.020 |
Why?
| | Mice | 2 | 2024 | 18297 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 99 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2009 | 74 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 329 | 0.020 |
Why?
| | Probability | 1 | 2010 | 309 | 0.020 |
Why?
| | Infant | 1 | 2023 | 10114 | 0.020 |
Why?
| | Morbidity | 1 | 2009 | 319 | 0.020 |
Why?
| | Advisory Committees | 1 | 2009 | 228 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 920 | 0.020 |
Why?
| | Suture Techniques | 1 | 2008 | 138 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 999 | 0.020 |
Why?
| | Postoperative Hemorrhage | 1 | 2008 | 106 | 0.020 |
Why?
| | Catheterization | 1 | 2007 | 179 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2010 | 594 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3206 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6073 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2488 | 0.010 |
Why?
| | Pyelonephritis, Xanthogranulomatous | 1 | 2004 | 3 | 0.010 |
Why?
| | Ligation | 1 | 2004 | 88 | 0.010 |
Why?
| | Thrombectomy | 1 | 2004 | 79 | 0.010 |
Why?
| | Escherichia coli Infections | 1 | 2004 | 125 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2004 | 306 | 0.010 |
Why?
| | Washington | 1 | 2003 | 157 | 0.010 |
Why?
| | Popliteal Vein | 1 | 2001 | 5 | 0.010 |
Why?
| | Protein S Deficiency | 1 | 2001 | 8 | 0.010 |
Why?
| | Antithrombin III Deficiency | 1 | 2001 | 8 | 0.010 |
Why?
| | Adolescent | 2 | 2006 | 22557 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1827 | 0.010 |
Why?
| | Protein C Deficiency | 1 | 2001 | 11 | 0.010 |
Why?
| | Hospitalization | 1 | 2012 | 2475 | 0.010 |
Why?
| | Trismus | 1 | 2001 | 2 | 0.010 |
Why?
| | Hospital Charges | 1 | 2001 | 45 | 0.010 |
Why?
| | Causality | 1 | 2001 | 128 | 0.010 |
Why?
| | Cellulitis | 1 | 2001 | 55 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 2001 | 289 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2004 | 287 | 0.010 |
Why?
| | Creatine Kinase | 1 | 2000 | 70 | 0.010 |
Why?
| | Necrosis | 1 | 2001 | 243 | 0.010 |
Why?
| | Child, Preschool | 1 | 1995 | 11913 | 0.010 |
Why?
| | Eye Diseases | 1 | 2001 | 100 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2001 | 429 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 294 | 0.010 |
Why?
| | Anesthesia, General | 1 | 2000 | 124 | 0.010 |
Why?
| | Rectum | 1 | 2000 | 180 | 0.010 |
Why?
| | Myocardial Ischemia | 1 | 2000 | 286 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 217 | 0.010 |
Why?
| | Blindness | 1 | 1998 | 51 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2001 | 1271 | 0.010 |
Why?
| | Drug Evaluation | 1 | 1997 | 78 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2001 | 1488 | 0.010 |
Why?
| | Electrocardiography | 1 | 2000 | 667 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 219 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 247 | 0.010 |
Why?
| | Decision Making | 1 | 2003 | 993 | 0.010 |
Why?
| | Child | 1 | 1995 | 22693 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1849 | 0.010 |
Why?
| | Hemorrhage | 1 | 1998 | 825 | 0.010 |
Why?
| | Smoking | 1 | 1998 | 1486 | 0.010 |
Why?
|
|
Matsumura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|